Business
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n New York, NY, and Tel Aviv, ISRAEL, April 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd. applauds the Biden Administration’s Acceleration of Whole-of-Government Effort to Prevent, Detect, and Treat Long COVID announced on April 5th, 2022. The Company believes that the tremendous burden of Long COVID, recently estimated to affect over 22 million Americans and leading directly to over 7 million Americans with disabling Long COVID with a total personal financial burden of over $380 billion dollars, must be met with an overwhelming investment in new therapies for Long COVID with a government focus akin to Operation Warp Speed. Concurrent with this announcement, the Company announced that the US FDA recently granted a new Certificate of Free Sale for its proprietary 3CL protease inhibitor, immune support dietary supplement Tollovid® that allows for both acute dosing for immune support (12 pills per day for 5 days) and chronic daily dosing for maintenance (2 pills per day) on the same label. A recent case study was reported by Dr. John Mabayoje outlining the potential benefit of Tollovid in the treatment of debilitating Long COVID in which a 49-year old female Long COVID sufferer who was chronically testing COVID positive by PCR for over 3 months from initial COVID diagnosis and experienced Long COVID symptoms including low energy, excessive somnolence, easy fatigability, myalgia, and headaches. This patient saw complete resolution of all Long COVID symptoms following the initial 5-day dosing regimen of Tollovid, immediately afterwards tested negative by COVID PCR, and was able to return to her job as a flight attendant immediately afterwards while staying healthy for four months to date following Tollovid intervention. The Company intends to conduct further research in this area with Tollovid, and is currently working to turn Tollovid into an OTC drug. Tollovid is currently not approved to diagnose, treat, prevent or cure any disease, including COVID or Long COVID.  Additionally the Company is developing the separate, but related, therapeutic drug candidate Tollovir™ for the treatment of hospital...